Q2 2024 Corcept Therapeutics Inc Earnings Call Transcript
Key Points
- Corcept Therapeutics Inc (CORT) reported a 39% increase in revenue for Q2 2024, reaching $163.8 million.
- Net income for Q2 2024 was $35.5 million, up from $27.5 million in the same quarter of the previous year.
- The company has increased its 2024 revenue guidance to $640 million to $670 million.
- Significant progress in clinical development programs, including the CATALYST study showing a higher prevalence of hypercortisolism than previously assumed.
- Positive results from the GRACE study, demonstrating relacorilant's efficacy and safety in treating Cushing's syndrome.
- Ongoing legal battle with Teva over the marketing of a generic version of Korlym, with uncertainty around the timing of the Federal Circuit Court's decision.
- Potential market entry of additional generic competitors, which could impact revenue.
- Delay in the NDA submission for relacorilant to Q4 2024 due to the decision to include data from the GRADIENT trial.
- The CATALYST study's treatment results are still pending, which could affect future revenue projections.
- Challenges in expanding the market for Korlym and relacorilant, including pricing considerations for a potentially larger patient population.
Hello. Thank you for standing by, and welcome to Corcept Therapeutics conference call. (Operator Instructions)
I would now like to turn the call over to Atabak Mokari. You may begin.
Hello, everyone. Good afternoon, and thank you for joining us. Today, we issued a press release announcing our financial results for the second quarter and providing a corporate update. A copy is available at corcept.com. Our complete financial results will be available when we file our Form 10-Q with the SEC. Today's call is being recorded. A replay will be available at the Investors, Past Events tab of our website.
Statements during this call other than statements of historical fact are forward-looking statements based on our plans and expectations that are subject to risks and uncertainties, which might cause actual results to be materially different from those such statements express or imply. These forward-looking statements are described in today's press release and the risks and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
